

Decreto Rettore Università di Roma “La Sapienza” n. **3227/2021** pubblicato sulla G.U. – IV serie speciale n. 103 in data 28-12-2021.

Eleni Anastasiadou Curriculum Vitae

Rome, 25th January 2022

Part I – General Information

Full Name	Eleni Anastasiadou
Spoken Languages	Greek, Italian, English
ORCID profile	https://orcid.org/0000-0003-0212-6734

Part II – Education

Type	Year	Institution	Notes (Degree, thesis title)
Bachelor of Science	2004	Sapienza University, Rome	B.Sc. Thesis title: “Role of Epstein-Barr virus in the pathogenesis of primary effusion lymphomas”.
Doctorate in Experimental Medicine, 20° cycle	2009	Department of Experimental Medicine, Sapienza University, Rome, Italy.	Ph.D Thesis title: “Regulation of Epstein-Barr virus latency in B cell lymphomas of varied differentiation stages”.
Specialization in Microbiology and Virology	2014	Faculty of Medicine and Dentistry, Sapienza University, Rome, Italy.	Dissertation title: “Epstein-Barr virus infection and dysregulation of cellular microRNA: Implications for diagnosis and therapy of plasma cell neoplasms”.
National Scientific eligibility	2019	The Italian National Agency for the Evaluation of Universities and Research Institutes (ANVUR)	Eligibility for associate professor in the sector 06/A2, call 2018/2020 General Pathology and Clinical Pathology. Valid from 10/05/2019 to 10/05/2028.
National Scientific eligibility	2019	The Italian National Agency for the Evaluation of Universities and Research Institutes (ANVUR)	Eligibility for associate professor in the sector 06/N1, call 2018 Health professions Sciences and applied Medical technologies. Valid from 06/09/2019 to 06/09/2028.

Part III – Appointments

III A – Academic Appointments

Start	End	Institution	Position
2009	2010	Department of Experimental Medicine, Sapienza University, Rome	Post doctorate Fellow from Institut Pasteur Cenci Bolognetti
2010	2014	Department of Experimental Medicine, Sapienza University, Rome	Research fellow (assegnista di ricerca)

2014	2018	Department of Pathology, Institute for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA	Senior Research Associate
2018	2020	Department of Experimental Medicine, Sapienza University, Rome	Research fellow (assegnista di ricerca)
2021	present	Department of Experimental Medicine, Sapienza University, Rome	Fixed-term researcher, type A (RTDA).
2021	present	Ministry of Italian University Research, (MIUR)	Enrolled in the register of scientific experts REPRIZE for the basic research section

III B – Editorial/reviewer expertise

Year	Journal	Position
2017-2020	microRNA journal, Bentham publications	Editorial Board member
2020-2021	Frontiers in Cell and Developmental Biology Signaling (I.F.=6.684)	Guest Associate Editor, Special issue, Research topic: Targeting Developmental Pathways in Inflammation and Disease. https://www.frontiersin.org/research-topics/13051/targeting-developmental-pathways-in-inflammation-and-disease
2021-present	International Journal of Molecular Sciences for “Molecular Immunology”, (I.F.=5.924)	Topical Advisory Panel Member https://www.mdpi.com/journal/ijms/topic_editors/molecular_immunology .
2022-present	Frontiers in Immunology (I.F.=7.561)	Associate Editor https://loop.frontiersin.org/people/890679/overview
2018-present	Journal of Virology, Oncogene, International Journal of Cancer, International Journal of Molecular Sciences, Cell Cycle, Cells, Cancers, MiRNA journal, Future Virology, Scientific report, Stem Cells international, Cancers, MTNA, Frontiers in Cell and Developmental Biology, Clinical Immunology, Non-Coding RNA, Biomedicines.	Reviewer

Part IV – Teaching experience and supervision of undergraduate and graduate students

IV A – National

Year	Institution	Lecture/Course/Supervisor of Thesis
2011-2013	Sapienza University, Rome	Docent of Molecular Virology, Master II level (Prof. Guido Antonelli), Quantitative evaluation of microRNAs and experimental and diagnostic approaches based on microRNAs.
2019	Faculty of Pharmacy and Medicine, Sapienza University, Rome	Invited Lecturer: The dark side of the genome lightens up new ways to fight cancer. For the course: preclinical scientific methods, II year, Medicine and Surgery “F” International Medical School.

2019-present	Faculty of Medicine and Dentistry, Sapienza University, Rome	Docent of the Integrated Course of Basic Medical Scientific Methodology II (I year II semester), for students of Degree Course in Medicine and surgery “D” (In English).
2020-2021	Faculty of Pharmacy and Medicine, Sapienza University, Rome	Docent of Integrated Scientific Medical Methods (IV year I semester) of Degree Course in Medicine and surgery “A” (In English).
2021	PhD school in Translational Medicine and Oncology, Sant Andrea hospital, Sapienza University, Rome	Lecture: RNA-RNA networks in cancer and regenerative medicine: implications for the development of new targeted therapies.
2021-present	PhD school in Translational Medicine and Oncology, Sant Andrea hospital, Sapienza University, Rome	Board Member, Collegio del Dottorato.
2018-present	Sapienza University, Rome	Co-Supervisor for thesis of a PhD student in Life Science cycle XXXIV.
2018-2019	Sapienza University, Rome	Co-Supervisor for a Master degree (magistrale) thesis in Genetics and Molecular Biology.
2021-present	Sapienza University, Rome	Supervisor for a Master degree (magistrale) thesis in Genetics and Molecular Biology, Degree expected in 2022.
2020-present	Sapienza University, Rome	Supervisor for a Master degree (magistrale) thesis in Medical Biotechnologies, Degree expected in 2022.

IV B–International

2018	Harvard Medical School, Boston, USA	Docent, Course: Non-coding RNA and cancer, for undergrads, PhD students, Post-Docs, Faculty, or Staff.
2014-2018	Harvard Medical School, Boston, USA	Co-Supervisor of two graduate students
2022	Universidad De Granada, Spain	International PhD Examiner in Bioquímica y Biología molecular (B16.56.1). Thesis defense date: 28 January 2022.

Part V - Society memberships, Awards and Honors

Year	Title
2015-2019	Member of the Harvard Catalyst, The Harvard Clinical and Translational Science Center
2017-present	Associate Member of the American Association for Cancer Research (AACR)
2019-present	Member of the Italian Society of Translational Research and Paramedical Professions (SIRTEPS).
2020-present	Member of the Italian association of Immunology-Clinical Immunology and Allergology (SSICA)
2019	Reader’s choice: the best of Leukemia 2019: Anastasiadou E. et al, 2019, Leukemia
2021	Italian Association of Inventive and Innovative Women Award (ITWIIN 2021): Special mention and recognition in the health sector for the international patent W02019232160-RNA-AIDED IMMUNOTHERAPEUTICS.

Part VI – Patent and media coverage

2019	International patent W02019232160-RNA-AIDED IMMUNOTHERAPEUTICS,. Inventors: Anastasiadou (Harvard/Sapienza), Trivedi (Sapienza), Slack (Harvard Medical School, Boston, USA) https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019232160&_cid
------	--

	=P12-K87G3Z-72601-1
2018	<p>News coverage of Anastasiadou et al, Leukemia 2018.</p> <p>https://www.uniroma1.it/it/notizia/dallalleanza-sapienza-harvard-un-nuovo-approccio-terapia-del-cancro</p> <p>https://tg24.sky.it/salute-e-benessere/2018/07/12/tumori-terapia-sistema-immunitario.html</p> <p>https://oncolife.it/blog/novita-dalla-ricerca/immunoterapia-del-cancro-di-origine-infettiva-un-nuovo-approccio/</p> <p>https://www.researchitaly.it/en/success-stories/health-new-strategies-to-prevent-tumours-from-escaping-the-immune-system/</p> <p>https://www.sanitainformazione.it/salute/sapienza-harvard-immunoterapia/</p> <p>https://issuu.com/onbpress/docs/gdb_settembre_pagina_singola, Il giornale dei Biologi, 5, Settembre 2018, page 26</p>
2020	<p>News coverage of Anastasiadou et al, Clinical Cancer Research 2021.</p> <p>https://www.uniroma1.it/en/notizia/small-rna-big-hopes-discovered-new-molecule-slows-growth-aggressive-lymphomas</p> <p>https://www.quotidianosanita.it/scienza-e-farmaci/articolo.php?articolo_id=90401</p> <p>https://qds.it/tumori-scoperta-nuova-molecola-per-rallentare-linfomi-aggressivi/</p> <p>http://www.ilfarmacistaonline.it/scienza-e-farmaci/articolo.php?articolo_id=90401</p>

Part VII A– Presentations (Oral/invited/posters) in National and International conferences

Date	Oral presentations/Invited speaker/posters	Conference
12-13/09/2013	Oral presentation, Title: "Epstein-Barr virus alters phenotype of terminally differentiated B cells through miR-21 upregulation".	RNA Days National Symposium, Department of Biology and Biotechnology, Sapienza University, Rome. Organizer-Prof. Irene Bozzoni.
27/09/2013	Oral presentation, Title: "Epstein-Barr virus infection increases miR-21 in multiple myeloma cells".	Mini symposium on microRNA in health and diseases, Department of Experimental Medicine, Sapienza University, Rome, organizers, Prof. Pankaj Trivedi and Prof. Alberto Faggioni.
13/03/2015	Oral presentation, Title: "MicroRNA based tools for understanding and combating drug resistance in cancer".	Ludwig Cancer Center symposium at Harvard Medical School, Boston, USA
12-15/07/2015	Nominated fellow and Invited participant/speaker. Title: "The role of miR-21 and miR-155 in the pathogenesis of Diffuse Large B Cell Lymphoma (DLBCL): Development of antisense miR-21 and miR-155 therapeutics".	30 th Aspen Cancer Conference 2015, Aspen, Colorado, USA.
5/06/2017	Oral presentation, Title: "MicroRNA immuno-modulation of PD-L1 in hematological malignancies".	Ludwig Cancer center symposium, Harvard Medical School, Boston, USA
16/12/2021	Oral presentation, Title: "RNA-RNA network: from prediction strategies to in vitro validation".	Molecular Networks Working Group of the International Network Medicine Consortium organized by Dr. Edwin Silverman (Brigham and Women's Hospital, Harvard Medical School)
20-25/01/2013	Poster presentation, Title: "Differential regulation of mir-21 and miR-146a by Epstein-Barr virus encoded EBNA2".	Keystone Symposium, Noncoding RNAs in development and Cancer, Vancouver, Canada.
1-4/10/2017	Poster presentation, Title: "Epstein-Barr virus encoded EBNA2 alters immune checkpoint PD-L1 expression by	American Association for Cancer Research (AACR) special conference on Tumor Immunology and Immunotherapy, Boston,

	downregulating miR-34a in B cell lymphomas”.	USA.
25/02-01/03/2018	Poster presentation, Title: “Epstein-Barr virus encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B cell lymphomas”.	Keystone Symposium on Noncoding RNAs: form, function, physiology. Keystone, Colorado, USA.

Part VII B – Organizer of International workshop and conference

March 03-2018	Organizers: Drs. Eleni Anastasiadou and Frank J Slack. Titolo: “Non-coding RNA and Immuno-Oncology Mini-Symposium and Workshop”, Beth Israel Deaconess Medical Center, Harvard Medical School, location: CLS 421, BIDMC, Boston, USA.
July 3rd-6 th 2022	Organizing committee member for : “20th International Symposium on Epstein-Barr virus (EBV) and Associated Diseases, to be held in Siena, Italy. http://www.congressi.unisi.it/ebvconferencesiena/ http://www.congressi.unisi.it/ebvconferencesiena/organizing-committee/

Part VIII - Funding Information [grants as PI-principal investigator, co-PI or I-investigator] National and International

Year	Title	Program	Grant value
2004-2006	Role: <i>Investigator</i> . Project: Control of latency and replication of Epstein-Barr virus, PI: Prof. Alberto Faggioni	Associazione Italiana per la ricerca sul cancro (AIRC)	E. 105.000
2008	Role: <i>Investigator</i> . Project: Patogenesi, diagnosi e terapia della Sclerosi Multipla-National coordinator: Dott.ssa Francesca Aloisi	Progetto strategico, ISS, Ministry of Health, Italy	E. 145.000
2009	Role: <i>Investigator</i> . Project: Interazione tra il virus di Epstein Barr e cellula ospite: Regolazione dei microRNA da parte di proteine virali nei linfomi. Number: 2009YFL2EK_002, PI: Pankaj Trivedi	PRIN, Ministry of University and Research, Italy	E. 60.000
2009	Role: <i>Investigator</i> . Project: Analisi delle vie di segnalazione attivate nelle cellule microgliali dall'interazione CX3CL1/CX3CR1 e coinvolte nella loro attivazione e nelle loro funzioni, quali la proliferazione, la sopravvivenza, l'attività trascrizionale, la migrazione e la neuroprotezione, nel glioblastoma Number: 2009SX72KB_003, PI: Mainiero Fabrizio	PRIN, Ministry of University and Research, Italy	E. 60.000
2007-2009	Role: <i>Investigator</i> . Project: Identification of the cellular regulators of EBV latency: Implications for the therapy of EBV associated lymphomas. PI: Prof. Alberto Faggioni	Associazione Italiana per la ricerca sul cancro (AIRC)	E. 180.000
2012	Role: <i>Principal Investigator</i> . Progetti per Avvio alla Ricerca, C26N128SPT Project: Regolazione dei microRNA cellulari da virus erpetici: rationale per l'identificazione dei nuovi marcatori molecolari diagnostici.	Università degli Studi di ROMA "la Sapienza" Progetti di Ateneo	E. 2.000

2015-2016	Role: <i>Investigator</i> . Project: Immunomodulatory effects of MUC1 and discovery of microRNAs regulating MUC1 mediated signaling, in AML. PIs: David Avigan, Frank Slack, Jacalyn Rosenblatt	2015 CAO Pilot Grant, BIDMC/Harvard Medical School	\$ 100.000
2015-2019	Role: <i>Investigator</i> . Project: MicroRNA-based tools for understanding and combating drug resistance in cancer. PI: Frank Slack	BIDMC/Ludwig Center at Harvard Medical school grant	\$ 50.000/year
2015-2017	Role: <i>Co-PI</i> . Project: Tumor suppressive effects of a compound MRG-106, an inhibitor of miR-155, in Diffuse Large B-cell lymphoma. PI: Frank Slack	BIDMC, Harvard Medical School, miRagen Therapeutics Inc. Boulder, Colorado, USA	\$ 65.574
2020-present	Role: <i>Investigator</i> . Project: Meccanismi epigenetici sensibili, geni codificanti/non codificanti e mediatori paracrini nelle cellule staminali multipotenti del grasso epicardico. PI: Cinzia Marchese	PRIN, Ministry of University and Research, Italy	E. 213.655

Part IX – Research Activities

Keywords	Brief Description
-EBV -DLBCL -AML -Ovarian cancer -Immune checkpoints -microRNAs -Tumor immunogenicity -RNA aided immunotherapy -microfluidics chips -RNA-RNA networks	<p>In the last ten years or so, the unified theme of my research interest has been to understand molecular mechanisms underlying deregulation of miRNAs in different types of cancer. I have studied how: a) EBV alters cellular miRNAs and contributes to neoplastic phenotype, b) viral proteins influence miRNAs to regulate immune checkpoints like PD-L1 in EBV associated cancers and c) MUC1 oncoprotein upregulates PD-L1 through its effect on miRNAs in Acute myeloid leukemia (AML). More recently, I am engaged in understanding de-regulated oncogenic RNA-RNA interactions (miRNA/mRNA) in the pathogenesis of ovarian cancer and how these results can be translated into novel diagnostic, prognostic and therapeutic approaches.</p> <p>My main results throughout the years and current research activities are as follows:</p>
	<p>a) <i>EBV interaction with oncogenes and miRNAs in B cell lymphomas:</i> I discovered how EBV alters TCL1 oncogene in infected cells. Our data showed that the oncogenic viral proteins namely, EBNA2 and LMP1 can regulate cellular oncogenes and could be critical in designing efficient RNA based therapeutic strategies for EBV associated cancers. These results have been published in the following journals: <i>Anastasiadou et al, Oncogene, 2010, Boccellato et al, Journal of Virology 2007, Rosato*, Anastasiadou* et al, Leukemia 2012, *equal contribution.</i></p>
	<p>b) <i>EBV interaction with miRNAs in Multiple Myeloma:</i> In order to understand how EBV affects noncoding RNAs in multiple myeloma, my colleagues and I established the entire miRnome of both EBV infected and EBV negative multiple myeloma (MM) cell lines. We found that EBV infected MM have high miR-21 expression. This microRNA is the most frequently induced miRNA across different types of cancer. These findings were published in: <i>Anastasiadou et al, International Journal of Cancer 2015.</i></p>

	<p>c) Identification of a novel mechanism of tumorigenesis by which the MUC1 oncoprotein upregulates PD-L1 in AML cells. We found that through its effect on miR-34a and miR-200c, MUC1 can regulate PD-L1. We also found that downregulation of DICER and the loss of microRNA species regulate proteins with pro-oncogenic function such as PD-L1. These findings were published in <i>Pyzer et al, Leukemia, 2017</i></p>
	<p>d) EBV, EBNA2 and Immune checkpoint alteration by dysregulation of miRNAs: We have recently shown how EBV encoded EBNA2 downregulates cellular miRNAs and in particular miR-34a to increase PD-L1 expression, which helps the virus infected cells evade immune surveillance. I have developed and patented a novel tumor immunogenicity test system based on 3D microfluidic chips, with enormous translational bearings. Given the fact that cancer immunotherapy is successful only in about 30 % of cases, we are currently investigating the combinatorial potential of noncoding RNA and immune checkpoint blockers to reconstitute tumor immunogenicity. A joint international patent with my collaborators at Harvard Medical School in Boston, USA, and at Sapienza University emphasizes the conspicuous translational significance of these results. These exciting data have been reported in <i>Anastasiadou E. et al, Leukemia, 2019</i>. Gratifyingly, my paper in <i>Leukemia</i> was The readers' choice of 2019 as one of the best papers published that year in <i>Leukemia</i>. https://www.nature.com/articles/s41375-018-0178-x</p>
	<p>e) MiRNA-based cancer therapy, bench-to-bedside study. An oncogenic miRNA, namely miR-155 is highly expressed in diffuse large B-cell lymphoma (DLBCL). In a landmark study, I showed how Cobomarsen, an anti-miR-155 molecule is effective in reducing tumor burden in preclinical models and in a lymphoma patient. This anti-miR-155 molecule inhibited proliferation and induced apoptosis in ABC-DLBCL cell lines with high endogenous miR-155 expression and reduced tumor growth in xenografts. Most importantly, this compound was administered in a patient with DLBCL who was resistant to all previous therapeutic regimens. My results provided new insights for the safety and therapeutic potential of cobomarsen monotherapy for management of patients with refractory ABC-DLBCL. Presently, together with my collaborators at Harvard Medical School, we are investigating if cobomarsen can also be used for therapy in other types of lymphomas characterized by high miR-155 expression. The results are published in <i>Anastasiadou E et al, CCR, 2021</i>. https://www.uniroma1.it/en/notizia/small-rna-big-hopes-discovered-new-molecule-slows-growth-aggressive-lymphomas</p>
	<p>f) The role of miR-200c in the pathogenesis of ovarian cancer: Ovarian cancer is one of the most frequent and deadly cancers. I have embarked on a project to find out how miR-200c-3p is involved in the pathogenesis of this cancer. Our recent findings showed that miR-200c-3p has a dual role as an oncomiR and as tumor suppressor in two different types of OC cell lines, and in a pan-cancer level. In OC cells that do not express miR-200c-3p, the data suggest that overexpression of this miRNA can counteract the induced expression of PD-L1, c-myc and β-catenin by chemotherapy, targeted therapies and irradiation. On the other hand, inhibition of miR-200c-3p in OC cells expressing high endogenous levels of this miRNA induces apoptosis by increasing the expression of Calcineurin oncosuppressor. These data have significant translational implications and underpin the importance of miR-200c-3p in miRNA-based therapies. (<i>Anastasiadou E. et al, Cells, 2021; Anastasiadou E. et al, Genes, 2021</i>).</p>

	g) Development of novel 3D bioprinting and microfluidics chips to study the role of tumor microenvironment: In collaboration with Italian Institute of Technology (IIT), currently, we are setting the experimental protocols to produce new biomimetic models which will help us to better understand the role of the tumor microenvironment and immune cells in cancer and drug resistance. Such biomimetic models will be of great value to screen new therapeutic molecules and stratify patients for miRNA and immune checkpoint blocker-based combinatorial therapy.
	h) From bioinformatic analysis to personalized therapies for cancer treatment. In collaboration with Harvard Network Medicine consortium, Italian CNR, University of Turin and the Department of Spatial transcriptomics at Harvard Medical School, I am developing a project which include the construction of RNA-RNA networks combined with spatial transcriptomics carried out in FFPE cancer tissues to identify novel biomarkers and therapeutic targets for a more accurate diagnosis and prognosis of ovarian cancer. As a member of the Molecular Networks Working Group of the International Network Medicine Consortium, we have published the following article: Silverman E.K., Schmidt H.H.H.W., Anastasiadou E., et al; Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2020.

Part X – Summary and analysis of total scientific output

Product type	Number	Data Base	Start	End
Papers [international]	44	Scopus	2004	2022

Total Impact factor	330
Average Impact Factor per Product	7,50
Total Citations	1615
Average Citations per Product	36,70
First/last authorship	15
Hirsch (H) index	19
Normalized H index*	1

*H index divided by the academic seniority.

An up-to-date list of all publications can be found at:

<https://www.ncbi.nlm.nih.gov/myncbi/elena.anastasiadou.2/bibliography/public/>

Megiorni et al, Biomolecules (2022) is yet to appear on Pubmed.

Part XI Selected Publications for evaluation (20)

List of the publications selected for the evaluation. For each publication report title, authors, reference data, journal IF (if applicable), citations, press/media release (if any). Journal Impact factor of the year of publication, based on Journal of citation report (JCR/WOS) and number of citations according to Scopus.

1. Camero S, Vitali G, Pontecorvi P, Ceccarelli S, **Anastasiadou E**, Cicchetti F, Flex E, Pomella S, Cassandri M, Rota R, Marampon F, Marchese C, Schiavetti A, Megiorni F. Dnmt3a and dnmt3b targeting as an effective radiosensitizing strategy in embryonal rhabdomyosarcoma [Article]. **Cells**. 2021;10(11). doi:10.3390/cells10112956. **I.F.:** 6,6 **Citations:** 0

2. **Anastasiadou, E***; Ceccarelli, S.; Messina, E.; Gerini, G.; Megiorni, F.; Pontecorvi, P.; Camero, S.; Onesti, M.G.; Trivedi, P.; Faenza, M., et al. MiR-200c-3p maintains stemness and proliferative potential in adipose-derived stem cells by counteracting senescence mechanisms. *PLoS ONE* 2021, 16, doi:10.1371/journal.pone.0257070. I.F.: 3,2 Cit: 0
***Corresponding author**

3. **Anastasiadou E***, Messina E, Sanavia T, Labruna V, Ceccarelli S, Megiorni F, Gerini G, Pontecorvi P, Camero S, Perniola G, Venneri MA, Trivedi P, Lenzi A, Marchese C. Calcineurin gamma catalytic subunit ppp3cc inhibition by mir-200c-3p affects apoptosis in epithelial ovarian cancer [Article]. *Genes*. 2021;12(9). doi:10.3390/genes12091400. I.F.: 4,096 Citations: 1
***Corresponding author**

4. Megiorni F, Camero S, Pontecorvi P, Camicia L, Marampon F, Ceccarelli S, **Anastasiadou E**, Bernabò N, Perniola G, Pizzuti A, Panici PB, Tombolini V, Marchese C. Otx015 epi-drug exerts antitumor effects in ovarian cancer cells by blocking gnl3-mediated radioresistance mechanisms: Cellular, molecular and computational evidence [Article]. *Cancers*. 2021;13(7). doi:10.3390/cancers13071519. I.F.: 6,639 Citations: 2

5. **Anastasiadou E***, Messina E, Sanavia T, Mundo L, Farinella F, Lazzi S, Megiorni F, Ceccarelli S, Pontecorvi P, Marampon F, Di Gioia CRT, Perniola G, Panici PB, Leoncini L, Trivedi P, Lenzi A, Marchese C. Mir-200c-3p contrasts pd-l1 induction by combinatorial therapies and slows proliferation of epithelial ovarian cancer through downregulation of β -catenin and c-myc [Article]. *Cells*. 2021;10(3):1-21. doi:10.3390/cells10030519. I.F.: 6,6 Citations: 2, ***Corresponding author**

6. **Anastasiadou E**, Seto AG, Beatty X, Hermreck M, Gilles ME, Stroopinsky D, Pinter-Brown LC, Pestano L, Marchese C, Avigan D, Trivedi P, Escolar DM, Jackson AL, Slack FJ. Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth in Vitro and in Vivo [Article]. *Clinical Cancer Research*. 2021;27(4):1139-1149. doi:10.1158/1078-0432.CCR-20-3139. I.F.: 12,531 Citations: 23

Press/media release:

<https://www.uniroma1.it/en/notizia/small-rna-big-hopes-discovered-new-molecule-slows-growth-aggressive-lymphomas>

https://www.quotidianosanita.it/scienza-e-farmaci/articolo.php?articolo_id=90401

<https://qds.it/tumori-scoperta-nuova-molecola-per-rallentare-linfomi-aggressivi/>

http://www.ilfarmacistaonline.it/scienza-e-farmaci/articolo.php?articolo_id=90401

7. Silverman, E.K.; Schmidt, H.H.H.W.; **Anastasiadou, E.**; Altucci, L.; Angelini, M.; Badimon, L.; Balligand, J.L.; Benincasa, G.; Capasso, G.; Conte, F., et al. Molecular networks in Network Medicine: Development and applications. *Wiley Interdisciplinary Reviews: Systems Biology and Medicine* 2020, 12, doi:10.1002/wsbm.1489. I.F.: 5 Cit: 57

8. Segal M, Biscans A, Gilles ME, **Anastasiadou E**, De Luca R, Lim J, Khvorova A, Slack FJ. Hydrophobically Modified let-7b miRNA Enhances Biodistribution to NSCLC and Downregulates HMGA2 In Vivo [Article]. *Molecular Therapy - Nucleic Acids*. 2020;19:267-277. doi:10.1016/j.omtn.2019.11.008. I.F.: 8,886 Citations: 14

9. Vescarelli E, Gerini G, Megiorni F, **Anastasiadou E**, Pontecorvi P, Solito L, De Vitis C, Camero S, Marchetti C, Mancini R, Benedetti Panici P, Dominici C, Romano F, Angeloni A, Marchese C, Ceccarelli S. MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by

targeting Neuropilin 1 [Article]. *Journal of Experimental and Clinical Cancer Research*. 2020;39(1). doi:10.1186/s13046-019-1490-7. I.F.: 11,161 Citations: 17

10. Nahas MR, Stroopinsky D, Rosenblatt J, Cole L, Pyzer AR, **Anastasiadou E**, Sergeeva A, Ephraim A, Washington A, Orr S, McMasters M, Weinstock M, Jain S, Leaf RK, Ghiasuddin H, Rahimian M, Liegel J, Molldrem JJ, Slack F, Kufe D, Avigan D. Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine [Article]. *British Journal of Haematology*. 2019;185(4):679-690. doi:10.1111/bjh.15818. I.F.: 5,518 Citations: 22

11. **Anastasiadou E**, Stroopinsky D, Alimperti S, Jiao AL, Pyzer AR, Cippitelli C, Pepe G, Severa M, Rosenblatt J, Etna MP, Rieger S, Kempkes B, Coccia EM, Sui SJH, Chen CS, Uccini S, Avigan D, Faggioni A, Trivedi P, Slack FJ. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas [Article]. *Leukemia*. 2019;33(1):132-147. doi:10.1038/s41375-018-0178-x. I.F.: 8,665 Citations: 76

Press/media release:

<https://www.uniroma1.it/it/notizia/dallalleanza-sapienza-harvard-un-nuovo-approccio-limmunoterapia-del-cancro>

<https://tg24.sky.it/salute-e-benessere/2018/07/12/tumori-terapia-sistema-immunitario.html>

<https://oncolife.it/blog/novita-dalla-ricerca/immunoterapia-del-cancro-di-origine-infettiva-un-nuovo-approccio/>

<https://www.researchitaly.it/en/success-stories/health-new-strategies-to-prevent-tumours-from-escaping-the-immune-system/>

<https://www.sanitainformazione.it/salute/sapienza-harvard-immunoterapia/>

https://issuu.com/onbpress/docs/qdb_settembre_pagina_singola, Il giornale dei Biologi, 5, Settembre 2018, page 26

Readers' choice: the best of Leukemia 2019:

<https://www.nature.com/articles/s41375-018-0178-x>

12. Trivedi, P.; Slack, F.J.; **Anastasiadou, E**. Epstein-Barr virus: From kisses to cancer, an ingenious immune evader. *Oncotarget* 2018, 9, 36411-36412, doi:10.18632/oncotarget.26381. I.F.:5,168 Cit: 6

13. Stroopinsky D, Rajabi H, Nahas M, Rosenblatt J, Rahimian M, Pyzer A, Tagde A, Kharbanda A, Jain S, Kufe T, Leaf RK, **Anastasiadou E**, Bar-Natan M, Orr S, Coll MD, Palmer K, Ephraim A, Cole L, Washington A, Kufe D, Avigan D. MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism [Article]. *Journal of Cellular and Molecular Medicine*. 2018;22(8):3887-3898. doi:10.1111/jcmm.13662. I.F.: 4,658 Citations: 7

14. **Anastasiadou E**, Faggioni A, Trivedi P, Slack FJ. The nefarious nexus of noncoding RNAs in cancer [Review]. *International Journal of Molecular Sciences*. 2018;19(7). doi:10.3390/ijms19072072. I.F.: 4,183 Citations: 35

15. Ayoubian H, Ludwig N, Fehlmann T, Menegatti J, Gröger L, **Anastasiadou E**, Trivedi P, Keller A, Meese E, Grässer FA. Epstein-Barr virus infection of cell lines derived from diffuse large B-cell lymphomas alters microRNA loading of the AGO2 complex [Article]. *Journal of Virology*. 2018;93(3). doi:10.1128/JVI.01297-18. I.F.: 4,324 Citations: 6

16. **Anastasiadou E**, Jacob LS, Slack FJ. Non-coding RNA networks in cancer [Review]. *Nature Reviews Cancer*. 2017;18(1):5-18. doi:10.1038/nrc.2017.99. **I.F.: 42.784, Citations: 700**

17. Pyzer AR, Stroopinsky D, Rosenblatt J, **Anastasiadou E**, Rajabi H, Washington A, Tagde A, Chu JH, Coll M, Jiao AL, Tsai LT, Tenen DE, Cole L, Palmer K, Ephraim A, Leaf RK, Nahas M, Apel A, Bar-Natan M, Jain S, McMasters M, Mendez L, Arnason J, Raby BA, Slack F, Kufe D, Avigan D. MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs [Article]. *Leukemia*. 2017;31(12):2780-2790. doi:10.1038/leu.2017.163. **I.F.: 10,023 Citations: 47**

18. **Anastasiadou E**, Garg N, Bigi R, Yadav S, Campese AF, Lapenta C, Spada M, Cuomo L, Botta A, Belardelli F, Frati L, Ferretti E, Faggioni A, Trivedi P. Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells [Article]. *International Journal of Cancer*. 2015;137(6):1491-1497. doi:10.1002/ijc.29489. **I.F.: 5,531 Citations: 27**

19. **Anastasiadou, E.**; Slack, F.J. Malicious exosomes. *Science* 2014, 346, 1459-1460, doi:10.1126/science.aaa4024. **I.F.: 33,611 Cit: 43**

20. Rosato, P*.; **Anastasiadou, E***.; Garg, N.; Lenze, D.; Boccellato, F.; Vincenti, S.; Severa, M.; Coccia, E.M.; Bigi, R.; Cirone, M., et al. Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2. *Leukemia* 2012, 26, 2343-2352, doi:10.1038/leu.2012.108. * Equal contribution. **I.F.: 10,164 Cit: 68**

Firma

A large black rectangular redaction box covering the signature area.